You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections
SBC: Combinati Incorporated Topic: NIAIDAbstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of a Highly Specific Dengue Diagnostic Test
SBC: Z-Quick, LLC Topic: NIAIDProject Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Direct-read monitor for airborne viral pathogens
SBC: AEROSOL DEVICES INC Topic: NIAIDAerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders
SBC: Cetya Therapeutics, Inc. Topic: NHLBIPROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology
SBC: POINT DESIGNS, LLC Topic: NICHDThe Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring
SBC: Toromedes, Inc Topic: NEIProject SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation
SBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHDEvolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
SBC: Novoron Bioscience, Inc. Topic: NINDS7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHDPROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health